Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 19-26

  Emery, Paul ^a,b   Burmester, Gerd R ^c   Bykerk, Vivian P ^d   Combe, Bernard G ^e   Furst, Daniel E ^f   Barré, Emilie ^g   Karyekar, Chetan S ^g   Wong, Dennis A ^g   Huizinga, Tom W J ^h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HOSPITAL FOR SPECIAL SURGERY   (United States)

^e UNIV MONTPELLIER   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; RHEUMATOID FACTOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; BREAST CARCINOMA; CARCINOID; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY FAILURE; LIMB ABSENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UTERUS CANCER; VIRUS INFECTION; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DRUG COMBINATION; EARLY INTERVENTION; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ABATACEPT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84918571233     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206106     Document Type: Article

References (34)

1. Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:59-69.
2. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol Suppl 2007;80:1-7.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biological agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
4. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
5. Orencia (250 mg powder for concentrate for solution for infusion) Summary of Product Characteristics. 2013. http://www.medicines.org.uk/emc/medicine/19714/ SPC/ (accessed 14 Apr 2013).
6. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
7. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of treatment. Diabetes Care 2014;37:1069-75.
8. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
9. Emery P, Spieler W, Stopinska-Polaszewska M, et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize study. Arthritis Rheum 2013;65(Suppl 10):2689.
10. Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 2014. Published Online First: 28 August 2014.
11. Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73:75-85.
12. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2014;24:17-25.
13. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
14. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
15. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383:321-32.
16. van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
17. Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a multicentre randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum 2011;63:S960-1.
18. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001;47:199-203.
19. [No authors listed] Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Med Etika Bioet 2002;9:12-19.
20. Title 21 - Food and drugs. Chapter I - Food and Drug Administration Department of Health and Human Services. Subchapter A - General. Part 50 Protection of human subjects. Code of Federal Regulations 2013.
21. Cutolo M, Nadler S. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 2013;12:758-67.
22. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
23. Goronzy JJ, Matteson EL, Fulbright JW, et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004;50:43-54.
24. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
25. Nash P, Nayiager S, Genovese MC, et al. Immunogenicity, safety, and effi cacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) 2013;65: 718-28.
26. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013;72:1897-904.
27. Orencia prescribing information. 2013. http://packageinserts.bms.com/pi/pi-orencia. pdf (accessed 28 Sep 2014).
28. Einarsson JT, Geborek P, Saxne T, et al. Sustained remission in anti-TNF treated rheumatoid arthritis patients. Observational data from southern Sweden. Arthritis Rheum 2011;63(Suppl 10):432.
29. Pomirleanu C, Ancuta C, Miu S, et al. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol 2013;32:665-70.
30. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008;59:32-41.
31. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol 2007;34:1670-3.
32. Furst DE, Pangan AL, Harrold LR, et al. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011;63:856-64.
33. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5.
34. Felson DT, Smolen JS, Wells G, et al . American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.